Informed Prostate Cancer Patient Support

Shorter Course of Post-Op Radiation May Work Well for Prostate Cancer Patients

Meta-Analysis Reaffirms Role of ADT With Radiotherapy in Prostate Cancer | MedPage Today

Mixed Results With RT Plus Short-Term ADT in Intermediate-Risk Prostate Cancer | MedPage Today

Cleveland Clinic study links gut microbiome and aggressive prostate cancer: Researchers uncover how diet, lifestyle modifications may lower risk of lethal disease -- ScienceDaily

Impact of prostate biopsy secondary pathology review on radiotherapy management - Siedow - - The Prostate - Wiley Online Library

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer | Biomarker Research | Full Text

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer - ScienceDirect

Gene Test Finds Gradations in High-Risk Prostate Cancer | MedPage Today

New Trials in Prostate Cancer: Could Your Patient Benefit?

Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysis | Prostate Cancer and Prostatic Diseases

PD65-08 IMPACT OF PLANT-BASED DIET ON PSA LEVEL: DATA FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY | Journal of Urology

Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients | Request PDF

Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure - ScienceDirect : Although radiation therapy is one of the most significant treatment modalities for localized prostate cancer, the prognostic factors for biochemical r…

In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification - PubMed

Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure - International Journal of Radiation Oncology, Biology, Physics

Cancers Strike US Fighter Pilots, Crews at Higher Rates, Air Force Finds - Defense One

Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration‐resistant prostate cancer - Pilling - - The Prostate - Wiley Online Library

Histologically benign PI‐RADS 4 and 5 lesions contain cancer‐associated epigenetic alterations - Şeref - - The Prostate - Wiley Online Library : Background The detection rate of clinically significant prostate cancer has improved with the use of multiparametric magnetic resonance imaging (mpMRI). Yet, even with MRI-guided biopsy 15%–35% of h...

Association of germline rare pathogenic mutations in guideline‐recommended genes with prostate cancer progression: A meta‐analysis - Shi - - The Prostate - Wiley Online Library

Targeted prostate cancer screening could benefit men with inherited cancer syndrome: Men who inherit an increased risk of cancer through ‘Lynch syndrome’ could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe. -- ScienceDaily : Men who inherit an increased risk of cancer through 'Lynch syndrome' could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe. Annual PSA tests were eight times more likely to spot cancer in men with genetic hallmarks of Lynch syndrome than those without. Experts say evidence could be incorporated into a targeted screening program in future.

Urinary Dribbling - Warnings, Causes & Solutions - YouTube

Is the Success of Adaptive Therapy in Metastatic Castrate Resistant Prostate Cancer Influenced by Cell-Type-Dependent Production of Prostate Specific Antigen? | bioRxiv

Targeted prostate cancer screening: Are we there yet? - Cancer Research UK - Cancer news

NCCN guidance on the initial management of low-risk, localized prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK

Exceptions to “early salvage” radiation treatment for recurrence after prostatectomy | THE "NEW" PROSTATE CANCER INFOLINK

Patient Loses Prostate After Biopsy Slide Switched; More

CLINICAL EXPERIENCE IN PROSTATE ULTRA-HYPOFRACTIONATED RADIOTHERAPY WITH AN ONLINE ADAPTIVE METHOD - ScienceDirect

Upfront Triplet Improves OS in Metastatic Castration-Sensitive Prostate Cancer | MedPage Today

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer | Lantheus Holdings, Inc.

Chances to hear from the new President and CEO of the Prostate Cancer Foundation | THE "NEW" PROSTATE CANCER INFOLINK

A Tubular Dual-Roller Bending Mechanism Toward Robotic Transurethral Prostate Biopsy | IEEE Journals & Magazine | IEEE Xplore X. Xiao et al., "A Tubular Dual-Roller Bending Mechanism Toward Robotic Transurethral Prostate Biopsy," in IEEE/ASME Transactions on Mechatronics, vol. 26, no. 5, pp. 2483-2494, Oct. 2021, doi: 10.1109/TMECH.2020.3040749. Abstract: Prostate biopsy procedures as a gold standard for early screening of prostate cancer often suffer from multipass needle perforations to irrelevant perineal tissue, high complication risk, and time consumption. To address these challenges, this article proposes a transurethral prostate biopsy robot that can deliver a flexible biopsy needle inside the prostate from different angles and thus obtain tissue samples from multiple locations. Emphasis is on the design and validation of the transurethral prostate biopsy robot with a detailed introduction of the working principle, mechanism modeling, and function testing. Phantom

Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all? - International Journal of Radiation Oncology, Biology, Physics

First targeted treatment approved for advanced prostate cancer on NHS in Scotland - Cancer Research UK - Cancer news

Great Strides in PSA Detection and Risk Stratification | MedPage Today

‘Gut bugs’ can drive prostate cancer growth and treatment resistance: Study unveils mechanism through which the microbiome contributes to prostate cancer progression -- ScienceDaily : Common gut bacteria can become 'hormone factories' - fuelling prostate cancer and making it resistant to treatment, a new study shows. Scientists revealed how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy -- by providing an alternative source of growth-promoting androgens, or male hormones. The findings, once further validated in the clinic, could provide new opportunities for the treatment of prostate cancer through manipulation of the microbiome.

Researchers discover how gut bacteria can enhance prostate cancer growth

Impact of diverticular disease on prostate cancer risk among hypertensive men | Prostate Cancer and Prostatic Diseases : Prostate cancer (PCa) is a heterogenous disease with multiple etiological factors playing a role in its development. Recently, chronic and systemic inflammatory conditions such as inflammatory bowel disease were identified as key risk factors influencing its development. The study aimed to evaluate the relationship between diverticular disease (DD) (local and acute inflammation) and PCa. Hypertensive patients with DD and hypertensive controls were identified between 1995 and 2010 from the Statewide Planning and Research Cooperative System database. Cohorts were queried for PCa incidence through 2015. Univariable and multivariable logistic regression analyses were used for determining independent predictors of PCa diagnosis. A total of 51,353 patients with DD and 111,541 controls were identified. In all, 6.26% of DD developed PCa, and 3.71% of controls developed PCa (

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial | Prostate Cancer and Prostatic Diseases

Commentary: Which Cancer Treatment Is Best? Selecting the Right Tool for the Job

Cancer breakthrough: Exercise may stop disease in its tracks - ECU Newsroom

Significant discovery shows how exercise can directly slow cancer growth

Research shows exercise-related proteins can suppress tumor growth -- ScienceDaily

Investigating suspected prostate cancer: improving GP-patient communication - Cancer Research UK - Cancer news

Early outcomes and decision regret using PSMA/MRI guided focal boost for prostate cancer SBRT - ScienceDirect

Disease Control With Cabozantinib Plus Atezolizumab in CRPC | MedPage Today

The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation - International Journal of Radiation Oncology, Biology, Physics : The clinical cell-cycle risk (CCR) score, which combines the University of California San Francisco Cancer of the Prostate Risk Assessment (CAPRA) and the cell cycle progression (CCP) molecular score, has been validated to be prognostic of disease progression for men with prostate cancer. This study evaluated the ability of the CCR score to prognosticate the risk of metastasis in men receiving dose-escalated radiation therapy (RT) with or without androgen deprivation therapy (ADT).

Too Many Black Men Are Dying From Prostate Cancer | MedPage Today

New Tests for Colon, Prostate Cancer Show Promise

#ESMO21 Expert Video Report on Prostate cancer - YouTube

ESMO 2021: PARPi data and their role in mono/combination therapies - YouTube

ESMO 2021: Updates in hormone-sensitive prostate cancer - YouTube : Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Prof ...

(40402) Inoreader - PARPi in PC - Case based testing and clinical decisions

Cabozantinib in combination with atezolizumab in patients with mCRPC - YouTube

Advances in prostate cancer in the last 10 years and a glimpse to the future - YouTube

Quality of life and safety in novel therapies for prostate cancer - YouTube

Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies | Prostate Cancer and Prostatic Diseases

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening | Prostate Cancer and Prostatic Diseases

Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide | Journal of Nuclear Medicine

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort | Journal of Nuclear Medicine

Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions | Journal of Nuclear Medicine

Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312) | Journal of Nuclear Medicine

Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer | Journal of Nuclear Medicine